Synlogic, Inc. SYBX
We take great care to ensure that the data presented and summarized in this overview for SYNLOGIC, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SYBX
Top Purchases
Top Sells
About SYBX
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Insider Transactions at SYBX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 29
2024
|
Mary Beth Dooley Head of Finance |
SELL
Open market or private sale
|
Direct |
79
-0.52%
|
$79
$1.4 P/Share
|
|
Apr 02
2024
|
Antoine Awad Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
372
-1.09%
|
$372
$1.73 P/Share
|
|
Apr 02
2024
|
Mary Beth Dooley Head of Finance |
SELL
Open market or private sale
|
Direct |
188
-1.22%
|
$188
$1.73 P/Share
|
|
Apr 03
2023
|
Michael Vangsted Jensen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,553
-5.16%
|
$0
$0.58 P/Share
|
|
Apr 03
2023
|
Antoine Awad Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,438
-7.93%
|
$0
$0.58 P/Share
|
|
Apr 03
2023
|
Aoife Brennan President and CEO |
SELL
Open market or private sale
|
Direct |
19,042
-6.92%
|
$0
$0.58 P/Share
|
|
May 24
2022
|
Michael Vangsted Jensen Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
9,500
+19.39%
|
$9,500
$1.12 P/Share
|
|
Apr 04
2022
|
Antoine Awad Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,650
-3.16%
|
$5,300
$2.45 P/Share
|
|
Apr 04
2022
|
Aoife Brennan President and CEO |
SELL
Open market or private sale
|
Direct |
8,894
-3.13%
|
$17,788
$2.45 P/Share
|
|
Mar 03
2022
|
Michael Vangsted Jensen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Feb 04
2022
|
Antoine Awad Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,820
+32.75%
|
-
|
|
Feb 04
2022
|
Aoife Brennan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
106,920
+27.33%
|
-
|
|
Apr 20
2021
|
Chau Quang Khuong Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,666,666
+31.08%
|
$4,999,998
$3.0 P/Share
|
|
Apr 20
2021
|
Orbimed Advisors LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,666,666
+31.08%
|
$4,999,998
$3.0 P/Share
|
|
Mar 10
2021
|
Antoine Awad Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+28.93%
|
-
|
|
Mar 10
2021
|
Aoife Brennan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
71,250
+28.66%
|
-
|
|
Mar 10
2021
|
Richard J. Riese Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+30.97%
|
-
|
|
Jan 26
2018
|
Orbimed Advisors LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
715,000
+26.05%
|
$6,435,000
$9.75 P/Share
|
Last 12 Months Summary
| Open market or private sale | 639 shares |
|---|